人急性髓系白血病細(xì)胞KG-1

細(xì)胞名稱

人急性髓系白血病細(xì)胞KG-1

貨物編碼

BFN60808690

產(chǎn)品規(guī)格

T25培養(yǎng)瓶x1

1.5ml凍存管x2

細(xì)胞數(shù)量

1x10^6

1x10^6

保存溫度

37℃

-198℃

運(yùn)輸方式

常溫保溫運(yùn)輸

干冰運(yùn)輸

安全等級(jí)

1

用途限制

僅供科研     2類

培養(yǎng)體系

DMEM高糖培養(yǎng)基+10%FBS+1%三抗

培養(yǎng)溫度

37℃

二氧化碳濃度

5%

簡介

人急性髓系白血病細(xì)胞KG-1取自59歲男性病人骨髓。該細(xì)胞源于DSMZ

注釋

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: FGFR genetic alteration cell panel (ATCC TCP-1034).

Part of: LL-100 blood cancer cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: TCGA-110-CL cell line panel.

Doubling time: ~38 hours (DSMZ).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Deep exome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

Discontinued: TKG; TKG 0400; true.

Derived from sampling site: Bone marrow.

基因突變

FGFR1OP2-FGFR1 gene fusion (PubMed=31160637).

NRAS p.Gly12Asp (c.35G>A) (PubMed=9379676).

Homozygous for TP53 c.672+1G>A; splice donor mutation (PubMed=1571549; CCLE; Cosmic-CLP).

HLA信息

/

STR信息

Amelogenin        X,Y

CSF1PO        7

D3S1358        15,16

D5S818        13

D7S820        8,10

D8S1179        13,14

D13S317        11,12

D16S539        10,11

D18S51        10,18 (PubMed=17254797)

10.2,18 (PubMed=25877200)

D21S11        28,29

FGA        22

Penta D        8,9

Penta E        7,13

TH01        7,8

TPOX        7,9

vWA        14,19

參考文獻(xiàn)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5

Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

BMC Cancer 18:940-940(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x

Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.

The LL-100 panel: 100 cell lines for blood cancer studies.

Sci. Rep. 9:8218-8218(2019)

PubMed=31395879; DOI=10.1038/s41467-019-11415-2

Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

Nat. Commun. 10:3574-3574(2019)